{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022315","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.257249+00:00","generated_at":"2026-06-22T05:25:58.759043+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome Q3 2022: First Sunosi revenue $16.8M, Auvelity launched, net loss $44.8M","bullets":["Sunosi U.S. net sales $16.8M (first reported by Axsome); total revenues $16.8M vs $0 prior year.","Net loss $44.8M ($1.07/share) vs $34.9M ($0.93) in Q3 2021; R&D $14.9M, SG&A $40.9M.","Cash $227.5M (vs $86.5M Dec 2021); expects cash to fund operations into 2025.","Auvelity launched Oct 20, 2022 for MDD; field force with prior psychiatry experience engaging prescribers.","Pipeline: AXS-07 NDA resubmission Q3 2023; AXS-05 ACCORD topline Q4 2022; solriamfetol ADHD trial Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022315","json":"https://secwatch.observer/filing/0000950170-22-022315.json","markdown":"https://secwatch.observer/filing/0000950170-22-022315.md","text":"https://secwatch.observer/filing/0000950170-22-022315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/0000950170-22-022315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/axsm-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:25:58.759043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c590af0a0f5afc5458241ac4ec2de744494ad9d1","claim":"Axsome Therapeutics, Inc. reported financial results for the three months ended September 30, 2022.","evidence_excerpt":"On November 7, 2022, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2022 and provided an update on the Company’s operations.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/0000950170-22-022315-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}